Arrowhead Pharmaceuticals Hits New 52-Week High at $43.33

Arrowhead Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 43.33 on October 30, 2025. This achievement underscores the company's notable performance in the pharmaceuticals and biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 3,756 million.
Over the past year, Arrowhead Pharmaceuticals has demonstrated impressive growth, with a performance increase of 72.62%, significantly outpacing the S&P 500's 18.13% gain during the same period. Despite being a loss-making entity, the company continues to attract attention within its industry.

Key financial metrics reveal a price-to-book ratio of 7.19, indicating how the market values the company's equity relative to its book value. Additionally, Arrowhead's debt-to-equity ratio stands at -0.56, reflecting a unique financial structure. However, the company does not offer a dividend yield, and its return on equity is reported at -30.51%. The stock's previous 52-week low was recorded at USD 9.57, highlighting the significant upward movement in its price.